SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BMY (bristol myers squibb) -- Ignore unavailable to you. Want to Upgrade?


To: Miljenko Zuanic who wrote (130)2/5/2018 12:24:54 PM
From: DewDiligence_on_SI  Read Replies (1) | Respond to of 194
 
Ex-US, Opdivo still has a formidable advantage relative to Keytruda in reimbursement agreements, which may partially protect 2018 Opdivo ex-US sales in NSCLC.

p.s.Eliquis had another blowout quarter.